SetPoint Medical, a Valencia, California-based biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, received an investment from venture capital firm New Enterprise Associates, Inc. (NEA).
NEA has joined the company’s syndicate of existing investors including Morgenthaler Ventures, Boston Scientific, Topspin Partners, Medtronic, and GlaxoSmithKline’s Action Potential Venture Capital Limited. In conjunction with the funding, Josh Makower, MD, General Partner at NEA, joined SetPoint Medical’s board of directors.
The financial details of the deal were not disclosed.
Led by Anthony Arnold, Chief Executive Officer, SetPoint Medical is developing a novel proprietary bioelectronic medicine platform to treat a variety of inflammation-mediated autoimmune diseases by activating the body’s natural Inflammatory Reflex to produce a systemic anti-inflammatory effect.